The U.S. FDA has approved Celcuity's Revtorpyk (gedatolisib) for patients with advanced HR+/HER2- breast cancer without PIK3CA mutations, marking the company's first approved drug. In Phase 3 trials, combining Revtorpyk with palbociclib and fulvestrant reduced the risk of disease progression or death by 76%, extending median progression-free survival to 9.3 months. Celcuity plans a commercial launch in late Q3 2026. Analysts view the biotech as a prime acquisition target for Big Pharma due to its high blockbuster potential and single-drug pipeline.
Revtorpyk FDA approval
- ▪Revtorpyk is approved for use in combination with fulvestrant, with or without Pfizer's Ibrance, which is also known as palbociclib
- ▪The U.S. Food and Drug Administration approved Celcuity's drug Revtorpyk, also known as gedatolisib, on July 14, 2026, marking the company's first product to gain market entry
- ▪Revtorpyk is approved for previously treated patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without any mutations in the PIK3CA gene
Gedatolisib clinical trial efficacy
- ▪Patients receiving Revtorpyk combined with palbociclib and fulvestrant achieved a median progression-free survival of 9.3 months compared to 2.0 months for those receiving fulvestrant alone
- ▪In the Phase 3 VIKTORIA-1 trial, Revtorpyk combined with palbociclib and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone
Celcuity commercialization strategy
- ▪Celcuity plans to commercially launch Revtorpyk in the third quarter of 2026 and has a sales force and commercial organization prepared
- ▪Revtorpyk is an intravenous drug that requires patients to travel to an infusion center, though Celcuity is developing an injectable formulation
- ▪Celcuity plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 to treat PIK3CA-mutated breast cancer
PAM pathway targeting mechanism
- ▪Unlike approved medicines that target a single component, Revtorpyk acts on multiple parts of the PI3K pathway to disrupt tumor cell energy regulation
- ▪Revtorpyk targets the PAM pathway by inhibiting class I PI3K isoforms as well as mTOR complexes mTORC1 and mTORC2
Acquisition target potential
- ▪Leerink Partners analyst Andrew Berens suggests Celcuity is a strategic acquisition target for large pharmaceutical companies due to its lack of other pipeline candidates
- ▪Celcuity CEO Brian Sullivan stated that gedatolisib can anchor the company's efforts to become a $10 billion company, though Celcuity currently has no other known drug candidates in its pipeline
Story comments
Loading comments…